Redeye gives an initial take on the first clinical results from the CARMA study with ELC-301.
EE headwinds from programme end-of-life and automotive market Mix effects and major FX revaluations ...
Vi inleder bevakning på Xoma, en svensk teknikleverantör som utvecklar landbaserade system för algod...
Redeye comments on the preliminary Q4 figures from Formpipe.
Redeye expects Smart Eye’s Q4 report, due 18 February, to show a 4% y/y sales growth and an EBITDA i...
Redeye is very pleased to see that OXE Marine has received another major order from the US Governmen...
Redeye provides a short comment on what is to be interpreted as a reverse profit warning from Cheffe...
Duell delivered slightly better figures than we had expected for the seasonally quiet Q1 of its fisc...
22% ARR growth and a solid 11% adj. EBITDA beat '25 guidance raised; adj.
Ahead of Fiskars' Q4 report, we nudge up our Q4 estimates slightly and expect the company to reach t...
Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phas...
Xplora does not meet the 90% threshold, so delisting and forced buy-out plans are on hold unless fur...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Redeye endorses today’s news that Cephagenix has secured funding of up to EUR9m and gives an initial...
